NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS
84.4% EXPERIENCED CLINICAL BENEFIT32.8% REPORTED NO EVIDENCE OF DISEASE
15.6% REPORTED TUMOR REGRESSION
36.1% REPORTED STABLE DISEASE
Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.
